2 TSX Stocks Bay Street Expects Could Double in July!

There are a few factors to know whether a stock could double in the next month, and these two hit all the boxes for Motley Fool investors.

| More on:
grow dividends

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

Earnings season is upon us yet again, and investors are hungry for stocks that could soar. After a year of growth stocks in 2020, investors across the world are greedy for more stocks that could double in a short period.

Now here at the Motley Fool, we don’t recommend buying a stock just to see it jump in a short period of time. There’s far too much risk. But luckily, there are still strong stocks that could double this month that are also solid long-term holds. So let’s look at three strong options.

CloudMD

The telehealth industry exploded during the pandemic, creating an ideal scenario for CloudMD Software & Services (TSXV:DOC). The company grew both organically and through acquisitions as demand increased. Even as the pandemic comes to an end, many believe telehealth will continue to be in great use. That’s because the method is not only faster, safer and cheaper, but also gives access to those living in remote communities. It’s just a win all around.

And that’s why CloudMD stock could double in July. Many sold their position with the worry of decreasing revenue. That simply hasn’t been the case, and so we’re left with an unnecessary pullback. Shares climbed 237% to all-time highs from when its Initial Public Offering (IPO), but have since slumped. As of writing, shares are now up 247% in the last year but have started to climb quickly.

But the stock is still incredibly cheap for Motley Fool investors at just $2.32 as of writing. And not only is it cheap by share price, but by fundamentals. Its price-to-book ratio sits at a cheap 2.6, and its revenue continues to hit records, most recently reaching a 187% increase year over year.

Analysts still believe it’s a solid buy, and believe this stock could double, or even more, very soon. Given that earnings are due soon, that could be this month alone.

Aurinia Pharmaceuticals

But it’s not just new industries flying high. This other stock could double because the pandemic is coming to a close, where production can finally be ramped up. That’s in the pharmaceutical industry, where due to COVID-19 there was a severe lack of research and development.

Aurinia Pharmaceuticals (TSX:AUP)(NASDAQ:AUPH) suffered during this time, unable to see production rise. But all that is about to change, and soon.

Shares fell after the company’s less than stellar earnings report. But its forward-looking statements lead Bay Street analysts to expect great things from this stock. Aurinia’s LUPKYNIS is the first FDA-approved oral medication for lupus nephritis. This life-saving treatment is expected to see immense revenue increases in the next year, leading Bay Street analysts to expect the stock to almost triple in the next year!

But shares are still cheap given all this potential. Trading at $15.75 at writing, the stock is down 23% in the last year. However, it recently climbed 18% in just a month. Meanwhile, its P/B ratio sits at 4.4, so it continues to be relatively cheap given all this potential for growth.

Bottom line

Both of these companies in the healthcare industry could very well soar not just in July, but beyond. That’s what we like here at the Motley Fool. No matter what you consider, the stock could double in the next month, but then soar beyond that in the next year and beyond.

These are strong companies that are perfect buy-and-hold options to add to your watchlist for years to come.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Amy Legate-Wolfe owns shares of Aurinia Pharmaceuticals. The Motley Fool has no position in any of the stocks mentioned.

More on Coronavirus

Business success with growing, rising charts and businessman in background
Coronavirus

1 Growth Stock Every Canadian Investor Should Consider Right Now

This growth stock saw shares pop 10% on June 20, as one analyst stated there is a significant opportunity to…

Read more »

Aircraft wing plane
Coronavirus

Bombardier Stock Merge: What it Means for Investors

Bombardier (TSX:BBD.B) stock went through a reverse stock split on June 13, turning 25 shares into one in one swift…

Read more »

Aircraft wing plane
Coronavirus

Air Canada (TSX:AC) Stock: Ready to Take Off?

While Air Canada is handling what it can control really well, there are many worsening macro headwinds that will likely…

Read more »

rail train
Coronavirus

Bull or Bear: Why Analysts Changed Their Tune on Aecon Stock

Analysts had been champing at the bit for the construction company, but the tides have turned.

Read more »

Biotech stocks
Coronavirus

Is Bellus Health Stock Still a Buy After 30% Earnings Jump?

The biotech continues to make progress on obtaining FDA approval for its chronic-cough therapy.

Read more »

grow dividends
Coronavirus

Goodfood Stock Likely to Double in 2022!

Goodfood (TSX:FOOD) stock has had a huge rise and fall in the last few years. But at $1.85 a share,…

Read more »

grow dividends
Coronavirus

Canfor Stock Pops 5% as Sales Climb 15% YOY

Canfor (TSX:CFP) stock remained positive about its future in the global lumber market after profits climb 15% year over year.

Read more »

edit Safety First illustration
Coronavirus

2 Crash-Proof TSX Stocks I’d Buy With $5,000

These two TSX stocks have proven they can handle this economic downturn and likely will continue to be safe far…

Read more »